Audit: QRS - Flaxseed for Health & Longevity

Audit conducted on 27/09/2026 10:01 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	risks_high hidden with comment quoting ER “No risk reaches High”; Low-tier prostate item kept as “signal”
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present; marker_1..12 and qualitative_item_1..6 instantiated
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against template shows only variable spans and the risks_high display:none (13.5) changed

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration quoted because value contains a colon
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0927-0919 -> 09/27/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Pregnancy qualifier trimmed to “(precaution)”, not dropped
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER Contraindications use no ranking notation inside parens
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 12 ER interactions represented; same-severity classes merged into 8 items
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example lists trimmed (e.g., losartan, garlic, bisacodyl dropped) but none removed entirely; vitamin E threshold kept
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER interactions use no ranking notation inside parens
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard regimen, Form, Single or split doses
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Protocol offers at least three actionable aspects; all three sets used
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Bowel effects, glucose/HbA1c, blood pressure from ER Practical Considerations
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER gives five time-to-effect aspects; all three sets used
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information (Practical Considerations)

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have ER items

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high set to display: none with ER-basis comment

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 12 ER table biomarkers listed
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 ER qualitative markers listed

Issues 27/09/2026 10:01

Pass rate 100.00%. No issues found.

Issues 27/09/2026 09:56

1. 2.7 — Unexplained medical jargon in contraindication: The contraindication at line 543 (“Current or past bowel obstruction, ileus, or esophageal or intestinal strictures”) uses “ileus” and “strictures” without plain-language explanation, although the ER glosses them (“a blocked bowel”, “narrowed segments”) and the adjacent dysphagia item is glossed.

Fixes 27/09/2026 09:56

1. 2.7 — Unexplained medical jargon glossed: Changed the contraindication “ileus, or esophageal or intestinal strictures” to “ileus (a blocked bowel), or esophageal or intestinal strictures (narrowed segments)”, using the ER’s own glosses.

Issues 27/09/2026 09:52

1. 2.7 / 13.3 — Unexplained thiocyanate jargon: risks_speculative (line 587) reads “thyroid effects from thiocyanate”, a mechanistic explanation using specialist chemistry jargon; marker_11_why (line 657) also uses “cyanide-derived thiocyanate” unexplained.
2. 4.5 — Sheet exceeds one page: Key Interactions (lines 554–565) reproduces all 12 ER interaction bullets without condensation, pushing the sheet well beyond one A4 page.
3. 12.3 — Effect-size qualifier in benefits: benefits_high (line 522) retains “modest” in “modest reduction in body weight and waist size”.

Fixes 27/09/2026 09:52

1. 2.7 / 13.3 — Removed thiocyanate jargon: Changed risks_speculative “thyroid effects from thiocyanate” to “thyroid effects”, and marker_11_why “Thyroid check with cyanide-derived thiocyanate” to “Thyroid check for cyanide breakdown product”.
2. 4.5 — Condensed Key Interactions list: Merged same-severity drug and supplement classes (blood thinners, blood pressure, glucose, laxatives/fiber) and trimmed example lists, reducing Key Interactions from 12 to 8 items while keeping every class, example list and severity.
3. 12.3 — Dropped effect-size qualifier: Changed benefits_high “modest reduction in body weight and waist size” to “reduction in body weight and waist size”.

Issues 27/09/2026 09:49

1. 8.4 — Added gloss in contraindication: The bowel obstruction item (QRS line 543) appends “(narrowed segments)”, which is not in the ER contraindication bullet (ER line 356) and adds elaboration beyond the key fact.

Fixes 27/09/2026 09:49

1. 8.4 — Removed added contraindication gloss: Deleted “(narrowed segments)” from the bowel obstruction item so it matches the ER contraindication bullet: “Current or past bowel obstruction, ileus, or esophageal or intestinal strictures”.

Issues 27/09/2026 09:46

1. 12.3 / 12.4 — Conflicted qualifiers in benefits: benefits_low (line 528) appends the parenthetical qualifier “(conflicted)” to the mortality, inflammation-marker and hot-flash items, although tiered benefit items must carry no qualifiers or parenthetical content.
2. 13.3 / 13.4 — Conflicted qualifier in risks: risks_low (line 584) appends the parenthetical qualifier “(conflicted)” to the prostate cancer and cancer-mortality item, although tiered risk items must carry no qualifiers or parenthetical content.

Fixes 27/09/2026 09:46

1. 12.3 / 12.4 — Conflicted qualifiers in benefits: Removed the parenthetical “(conflicted)” from the mortality, inflammation-marker and hot-flash items in benefits_low.
2. 13.3 / 13.4 — Conflicted qualifier in risks: Removed the parenthetical “(conflicted)” from the prostate cancer and cancer-mortality item in risks_low.

Issues 27/09/2026 09:42

1. 8.4 — Redundant gloss in contraindication: Line 543 adds “(a blocked bowel)” after “ileus”, an elaboration absent from the ER contraindication bullet (ER line 356) and redundant with the preceding “bowel obstruction”.

Fixes 27/09/2026 09:42

1. 8.4 — Redundant gloss removed: Removed “(a blocked bowel)” after “ileus” in the bowel-obstruction contraindication, matching the ER bullet “Current or past bowel obstruction, ileus, or esophageal or intestinal strictures”.

Issues 27/09/2026 09:39

1. 1.1 — Blood-pressure timing qualifier dropped: time_3_value “Beyond 20 weeks” (QRS line 508) omits the ER’s “greatest”, since the ER states “blood pressure greatest beyond 20 weeks”, implying no effect before 20 weeks.
2. 4.5 — Key Interactions exceed page budget: The 12 Key Interactions items (QRS lines 554-565) keep long definitional glosses (e.g., “blood thinners that slow clotting”, “a thyroid hormone”, “a heart-rhythm drug”), which pushes the sheet well past one A4 page instead of being condensed.

Fixes 27/09/2026 09:39

1. 1.1 — Blood-pressure timing qualifier restored: Changed time_3_value from “Beyond 20 weeks” to “Greatest beyond 20 weeks” to match the ER wording.
2. 4.5 — Key Interactions condensed: Removed the definitional glosses from the anticoagulant/antiplatelet item and the oral-medication item. All example drugs and severity classes are kept.

Issues 27/09/2026 09:36

1. 11.4 — Redundant time-to-effect sub: time_3_sub (line 511) “Reduction greatest beyond 20 weeks” repeats time_3_value “Beyond 20 weeks” instead of naming the related benefit, unlike time_1_sub and time_2_sub.

Fixes 27/09/2026 09:36

1. 11.4 — Redundant time-to-effect sub: Replaced time_3_sub “Reduction greatest beyond 20 weeks” with “Lower systolic and diastolic blood pressure”, naming the related benefit from the ER.

Issues 27/09/2026 09:33

1. 11.2 — Time to effect misordered: The Time to Effect cells (QRS lines 480-514) follow ER order (cholesterol, blood pressure, glucose) rather than benefit magnitude; constipation relief, the largest-magnitude High benefit (weekly bowel movements 2 to 7, ER line 177) with an ER time to effect of “Bowel effects within days” (ER line 416), is omitted while the smallest effect (LDL cholesterol, -4.2 mg/dL) is placed first.

Fixes 27/09/2026 09:33

1. 11.2 — Time to effect reordered: Replaced the cholesterol cell with “Bowel effects / Within days / Relief of chronic constipation” (ER Practical Considerations) and reordered the cells by benefit magnitude: bowel effects, then glucose and HbA1c, then blood pressure.

Issues 27/09/2026 09:30

1. 11.1 / 11.2 — Time to effect misselected, misordered: QRS lines 483–511 show bowel effects, glucose and blood pressure in order of onset speed, omitting cholesterol (ER line 416), the ER’s lead High benefit; cells are not picked and ordered by the magnitude of the related benefit.

Fixes 27/09/2026 09:30

1. 11.1 / 11.2 — Time to effect reselected, reordered: Replaced the bowel-effects cell with Cholesterol (within 4–12 weeks, ER line 416) and reordered the cells to Cholesterol, Blood pressure, Glucose and HbA1c, following the ER’s order of High benefits.

Issues 27/09/2026 09:27

1. 2.7 — Unexplained specialist terms: “strictures” in Contraindications (line 543) is left unexplained although the ER glosses it as “narrowed segments”, and “vitamin B6 antagonism” in Risks (line 587) is specialist wording where the ER offers “a vitamin B6 blocker”.
2. 2.15 — Lay phrase in lede: The at-a-glance text (line 433) says “bowel blockage” instead of the clinical term “bowel obstruction” used in the ER Conclusion and Risks sections.
3. 11.1 / 11.2 — Time-to-effect selection and order: The Time to effect cells (lines 480-514) leave out bowel/constipation relief (“Bowel effects within days”), the High benefit with the largest magnitude, and show cholesterol instead. The cells also follow the ER listing order (cholesterol, blood pressure, glucose) rather than effect size.

Fixes 27/09/2026 09:27

1. 2.7 — Unexplained specialist terms: Added the ER gloss “(narrowed segments)” after “esophageal or intestinal strictures” in Contraindications, and changed “vitamin B6 antagonism” to “vitamin B6 blocking” in Risks.
2. 2.15 — Lay phrase in lede: Changed “bowel blockage” to “bowel obstruction” in the at-a-glance text.
3. 11.1 / 11.2 — Time-to-effect selection and order: Replaced the cholesterol cell with “Bowel effects / Within days / Relief of chronic constipation” and reordered the cells by effect size: bowel effects, then glucose and HbA1c, then blood pressure.

Issues 27/09/2026 09:25

1. 2.7 — Unexplained jargon “ileus”: The second contraindication (QRS line 543) uses “ileus” without explanation, although the ER glosses it as “a blocked bowel” (ER line 292).

Fixes 27/09/2026 09:25

1. 2.7 — Unexplained jargon “ileus”: Changed the second contraindication from “ileus” to “ileus (a blocked bowel)”, using the ER’s own gloss.

Issues 27/09/2026 09:22

1. 2.7 — Unexplained ALA acronym: “ALA” appears without explanation in risks_low (line 584, “signal from high ALA”) and marker_9_why (line 647, “Shows how little ALA converts”), jargon a lay reader cannot decode.

Fixes 27/09/2026 09:22

1. 2.7 — Unexplained ALA acronym: Replaced “high ALA” with “high plant omega-3 intake” in risks_low and “Shows how little ALA converts” with “Shows how little plant omega-3 converts” in marker_9_why, matching the ER’s own plain-language wording.